Addressing the unmet clinical need for low-volume assays in early diagnosis of pancreatic cancer

• DOI: 10.3389/fgstr.2023.1258998
• Publication Date: 2023-09-20T04:47:01Z
• Authors: Daniel A. Sheik; Kaleb Byers; Mini Thomas; Ummadisetti Chinn...; Kelli Ifuku; Kimberly Kirkwood; Mohammed Al-Haddad; Charles S. Craik; V. Jo Davisson
• Keywords: 0301 basic medicine; Biomedical and Clinical Sciences; Prevention; pancreatic cystic lesions; Clinical Sciences; pancreatic cancer; rule-out; 610; RC799-869; Diseases of the digestive system. Gastroenterology; rule-in; surface-enhanced Raman spectroscopy; Article; 4.1 Discovery and preclinical testing of markers and technologies; Pancreatic Cancer; 03 medical and health sciences; Rare Diseases; dysplasia; Clinical Research; Biomedical Imaging; Digestive Diseases; Cancer; 4.2 Evaluation of markers and technologies; early diagnosis

The incidental detection of pancreatic cysts, an opportunity for the early cancer, is increasing, owing to aging population and improvements in imaging technology. classification cystic precursors currently relies on cyst fluid evaluations, including cytology protein genomic analyses. However, there are persistent limitations that obstruct accuracy quality information clinicians, limited volume complex, often acellular, proteinaceous milieu comprises fluid. constraints available clinical assays lead clinicians subjective inconsistent application diagnostic tools, which can contribute unnecessary surgery missed cancers. Herein, we describe pathway toward diagnosis, requirements several clinically some analytical each assay. We then discuss current future work novel markers methods, how expand utility samples. Results ongoing studies applying SERS as a mode suggest 50 µL more than sufficient accurately rule out non-mucinous cysts with no malignant potential from further evaluation. This process expected leave analyze follow-up, rule-in panel development stratify grades dysplasia mucinous improve decision-making.